Ceftriaxone

Section: 6. Anti-infective medicines > 6.2. Antibacterials > 6.2.2. Watch group antibiotics

EMLc | Codes ATC: J01DD04

Indication	Typhoid fever Code ICD11: 1A07
INN	Ceftriaxone
Type de médicament	Chemical agent
Groupes d'antibiotiques	WATCH
Type de liste	Liste de base
Additional notes	*Do not administer with calcium and avoid in infants with hyperbilirubinaemia.
Formulations	**Parenteral > General injections > unspecified:** 250 mg in vial powder for injection (as sodium salt) ; 500 mg in vial powder for injection (as sodium salt) ; 1 g in vial powder for injection (as sodium salt) ; 2 g in vial powder for injection (as sodium salt) (EML)
Historique des statuts LME	Ajouté pour la première fois en 2019 (TRS 1021) Modifié en 2021 (TRS 1035) Modifié en 2023 (TRS 1049)
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Limite d'âge	>41 weeks corrected gestational age
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets.
Wikipédia	Ceftriaxone
DrugBank	Ceftriaxone

Recommandation du comité d'experts

In consideration of the review of the age appropriateness of formulations of medicines on the EMLc, and the comparison report of the EML versus EMLc, the Expert Committee recommended changes to the EMLc for addition of new, age-appropriate formulations and strengths of existing essential medicines, deletion of unavailable or age-inappropriate formulations and strengths, and other listing modifications as proposed in the application. The Committee also endorsed the proposals for further review of the public health relevance and evidence for specific medicines for use in children for potential future consideration for inclusion on the EMLc. The Committee noted and welcomed the ongoing review being coordinated by the Secretariat for the remaining sections of the EMLc for consideration by the 2025 Expert Committee. As a result of the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - replacing the oral liquid formulation of azithromycin (200 mg/5 mL) with powder for oral liquid 200 mg/5 mL on the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ciprofloxacin (solid oral dosage form 100 mg (as hydrochloride)) to the EMLc.

Recommandations de la LME : Typhoid fever

Premier choix	Second choix
ciprofloxacin	
azithromycin	
ceftriaxone	

